🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Innovist raises Rs 136 Cr led by ICICI Venture; Accel exits

EntrackrEntrackr · 8m ago
Innovist raises Rs 136 Cr led by ICICI Venture; Accel exits
Medial

Innovist, the parent company of Bare Anatomy, has raised Rs 136 crore (approximately $16 million) in a Series B funding round led by ICICI Venture. The round saw participation from Mirabilis Investment Trust, Niveshaay Investment, and existing backer Sauce. The funding round includes both primary and secondary components and will be directed toward product development, business growth, and team expansion, the company said in a media release. In the round, the company provided exit to Accel, which came in via their seed program (atoms). Rohit Chawla, founder and CEO, said that Innovist is one of the fastest-growing BPC (beauty and personal care) firms in the country and aims to cross Rs 300 crore in revenue by FY25. While the company has not yet filed its annual statements for FY24, it reported operational revenue of Rs 36.53 crore in FY23, along with a loss of Rs 16.87 crore. Innovist, previously known as Onesto Labs, was founded in 2018 by Chawla, Sifat Khurana, and Vimal Bhola. The company provides personal care products and currently manages three brands: Bare Anatomy, Chemist at Play, and Sunscoop. To date, Innovist has raised over $26 million, including a $7 million Series A round led by the Amazon Smbhav Venture Fund. According to startup data platform TheKredible, prior to this round, Sauce.VC was the largest external stakeholder, followed by 72 Ventures, Accel India, and the Amazon Smbhav Fund. It competes with D2C beauty brands like Minimalist, Mamaearth, Wow Skin Science, and Sugar Cosmetics.

Exclusive: Bare Anatomy parent Innovist kicks off Series B round

EntrackrEntrackr · 9m ago
Exclusive: Bare Anatomy parent Innovist kicks off Series B round
Medial

Innovist, the parent company of Bare Anatomy, Chemist at Play, and Sunscoop, is raising Rs 49.25 crore (approximately $5.7 million) in its Series B round. This marks the first round of investment for the Gurugram-based company in 2025. The board at Innovist has passed a special resolution to issue 72,223 Series B compulsory convertible preference shares at an issue price of Rs 6,819 each, raising Rs 49.25 crore, according to its regulatory filing accessed from the Registrar of Companies (RoC). IVen Amplifi Fund (managed by ICICI Ventures Fund) will lead the round with Rs 19.47 crore, while Mirabilis Investment Trust will contribute Rs 10.1 crore. Sauce.VC and Niveshaay Sambhav Fund will also participate, investing Rs 8.75 crore and Rs 10 crore, respectively. The fresh proceeds will be utilized for recruitment, operations, sales, marketing, and other general corporate purposes, as decided by the board. According to Entrackr estimates, the company will be valued at approximately $140 million post-allotment. This capital infusion appears to be part of a larger funding round, with the potential for additional investments that could further impact its valuation. Founded in 2018 by Rohit Chawla, Sifat Khurana, and Vimal Bhola, Innovist—formerly known as Onesto Labs—offers personal care products. It currently operates three brands: Bare Anatomy, Chemist at Play, and Sunscoop. Innovist has raised over $16 million to date, including a $7 million Series A round led by the Amazon Smbhav Venture Fund. According to the startup data intelligence platform TheKredible, prior to this round, Sauce.VC was the largest external stakeholder, followed by 72 Ventures, Accel India, and the Amazon Smbhav Fund. The company has not yet filed its annual statements for the previous fiscal year (FY24). In FY23, it reported operational revenue of Rs 36.53 crore, while its losses amounted to Rs 16.87 crore during the same period.

Bare Anatomy parent Innovist crosses Rs 300 Cr revenue in FY25, turns profitable

EntrackrEntrackr · 9d ago
Bare Anatomy parent Innovist crosses Rs 300 Cr revenue in FY25, turns profitable
Medial

Innovist, the parent company of Bare Anatomy, Chemist at Play, Sunscoop, and Vinci, reported strong financial performance in the fiscal year ended March 2025, with total revenue surpassing Rs 300 crore while turning profitable during the year. Innovist has posted over 2.8X year-on-year growth in its operating revenue to Rs 299 crore in FY25 from Rs 105.8 crore in FY24, according to its consolidated financial statements filed with the Registrar of Companies (RoC). Founded in 2018 by Rohit Chawla, Sifat Khurana, and Vimal Bhola, Innovist, formerly known as Onesto Labs, offers hair and skin products and currently operates four brands: Bare Anatomy, Chemist at Play, Sunscoop, and Vinci Botanicals. The sale of these products was the primary source of revenue for the company, accounting for 97.5% of total revenue or Rs 291.5 crore, while the remaining Rs 7.6 crore came from the shipping receipts. Innovist also earned Rs 2.34 crore from interest on current investments and other non-operating sources, taking its total income to Rs 301.4 crore. On the expense side, advertising remained the company’s largest cost head, rising 2.5X year-on-year to Rs 136.5 crore and accounting for over 45% of the total expenditure. The cost of materials, another key expense component, also surged 2.6X to Rs 78.5 crore during the year. Warehousing-related expenses nearly tripled during the fiscal year to Rs 24 crore, while employee benefit expenses stood at Rs 15 crore, accounting for just 5% of the total cost. Meanwhile, commission paid to sole buying agents for procuring raw materials surged over 19X to Rs 15.5 crore. Other overheads, including transportation, rent, IT expenses, and legal and professional fees, took total expenses to Rs 301 crore in FY25. The D2C house of brands recorded nearly threefold revenue growth in the previous fiscal. It also booked Rs 11.8 crore in deferred tax income. Together, these helped the company turn profitable, posting a Rs 12 crore profit compared to a Rs 12.5 crore loss in FY24. Its ROCE improved to -1.46%, while the EBITDA margin turned positive at 0.42% in FY25 with an EBITDA of Rs 1 crore. On a unit level, Innovist improved its expense-to-earning ratio to Rs 1.01 during the period. The Gurugram-based company reported current assets of Rs 116 crore, including cash and bank balances of Rs 46 crore, as of March 2025. According to startup data intelligence platform TheKredible, the Gurugram-based company has raised $30 million in funding to date, including a $16 million round in April this year through a mix of primary and secondary transactions led by ICICI Venture, which also provided an exit to its existing backer Accel. After a difficult 2024 for the D2C category, some of which is still unfolding for some, many others who survived seem to have learned some important lessons. While the high advertising expenses don’t indicate a drop in competitive intensity yet, the topline growth does point to a business with a more than foothold in the market now. A funding revival of sorts is also underway with some recent news in the category, but for Innovist, bigger prizes await if it can sustain the growth and keep improving margins steadily.

Exclusive: XYXX raises fresh funds led by Niveshaay Sambhav Fund

EntrackrEntrackr · 9m ago
Exclusive: XYXX raises fresh funds led by Niveshaay Sambhav Fund
Medial

Men-focused premium innerwear and lifestyle brand XYXX is raising Rs 30 crore ($3.6 million) in a funding round led by Niveshaay Sambhav Fund, with participation from Anicut Capital, DSG Consumer Fund, and Sauce Continuity Fund. The board at XYXX has passed a special resolution to issue 1,81,818 Series B2 CCPS at an issue price of Rs 1,650 each to raise the aforementioned sum, its regulatory filing accessed from the Registrar of Companies shows. Niveshaay Sambhav Fund will invest Rs 9.93 crore, while Anicut Capital, Sauce Continuity Fund, and DSG Consumer Partners will contribute Rs 7.95 crore, Rs 4.96 crore, and Rs 1.99 crore, respectively. The remaining amount will be invested by Singularity Growth, Selenium Trust, Veena Merchants, and Arun Venkatachalam HUF. XYXX will use these proceeds to meet the capex and working capital requirements for the ongoing operations. According to Entrackr's estimates, it will be valued at around Rs 820 crore post-allotment. XYXX is a lifestyle brand specializing in underwear, loungewear, and athleisure, crafted from premium fabrics. The company claims to have built a network of over 18,000 retailers across 50 cities. Besides its own website, XYXX retails on various marketplaces and claims to be among the top three innerwear brands. In FY23, the company launched its first store in central Mumbai and now plans to expand with new outlets in Indore and Bangalore. XYXX has raised Rs 250 crore to date, including Rs 110 crore led by Amazon Smbhav Venture Fund in May 2023. According to the startup data intelligence platform TheKredible, before this round, Sauce.vc was the largest external stakeholder, followed by DSG Consumer Fund and Amazon Smbhav Venture Fund. XYXX recorded a 25% year-on-year revenue growth, rising from Rs 105 crore in FY23 to Rs 131 crore in FY24. Simultaneously, the company trimmed its losses by 22.2% to Rs 35 crore in FY24.

Download the medial app to read full posts, comements and news.